BeOne Medicines (formerly BeiGene; Basel, Switzerland; Nasdaq: ONC) appears to have terminated a Phase I clinical trial for BG-60366, an orally administered chimeric degradation activation compound (CDAC) designed to degrade mutant epidermal growth factor receptor (EGFR) protein. A Phase I clinical trial assessing the drug candidate in patients with EGFR-mutant non-small cell lung cancer (NSCLC) has been listed as terminated on the clinicaltrials.gov platform, with the decision described as reflecting an "evaluation on business strategy" rather than safety issues.
The Phase I, open-label, multicenter, non-randomized trial had enrolled 33 participants before being halted ahead of its May 2026 primary completion date, with no efficacy, safety, or pharmacokinetic data released publicly.
The trial enrolled adults with histologically or cytologically confirmed advanced or metastatic NSCLC carrying EGFR activating mutations who had progressed on prior third-generation EGFR tyrosine kinase inhibitor (TKI) therapy. The safety expansion cohort specifically required documentation of EGFR resistance mutations, including the C797S substitution — a mechanism of acquired resistance to osimertinib (Tagrisso) that eliminates covalent binding at the drug's target cysteine residue. Prior treatment with fourth-generation EGFR-TKIs or other CDAC or PROTAC compounds targeting EGFR resistance mutations was an exclusion criterion.
Sites spanned the US, China, Australia, South Korea, Spain, Italy, Brazil, Thailand, Malaysia, and New Zealand, with enrollment active at institutions including Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Peter MacCallum Cancer Centre.
The CDAC modality itself presents specific early-phase challenges that may have been relevant. Oral bioavailability for compounds in this class is frequently suboptimal, and the efficiency of ternary complex formation between the degrader, target protein, and E3 ligase can be difficult to predict from preclinical models. A "hook effect" — reduced degradation activity at higher concentrations due to formation of unproductive binary complexes — is a known class liability. Whether any of these factors contributed to the decision to halt BG-60366 development cannot be established from the available public record.
Pipeline context
The BeiGene clinical trial termination of BG-60366 occurred during a period of deliberate portfolio rationalization at BeOne Medicines. The company, which rebranded from BeiGene and redomiciled to Basel, Switzerland in 2025, simultaneously shelved several other early-stage oncology programs including a pan-KRAS inhibitor, a MAT2A inhibitor, a CDK2 inhibitor, and an anti-CCR8 monoclonal antibody, as well as a Phase II rheumatoid arthritis study.